Utility of diffusion-weighted imaging to assess XXXX @entity12652 .

@entity1 @entity41 @entity39 @entity5 @entity12652 @entity157
The purpose of the present study was to evaluate whether diffusion-weighted imaging (DWI) can be used to assess @entity157 ( @entity157 ) @entity12652 (TACE). A total of 41 consecutive @entity1 were treated according to chemoembolization protocols. The follow-up was performed between six and eight weeks post-chemoembolization by multidetector computed tomography [or enhanced magnetic resonance imaging (MRI)] and DW-MRI on the same day. The presence of any @entity41 and the extent of @entity5 @entity39 were evaluated according to the European Association for the Study of the Liver. The apparent diffusion coefficient (ADC) values of the entire area of the treated mass and the vital and @entity5 tissues were recorded. Correlation coefficients were also calculated to compare the percentage of @entity39 with ADC values. The mean ADC values of the @entity5 tissues were 2.22  0.31 10(-3) mm(2)/sec and 1.42  0.25 10(-3) mm(2)/sec, respectively (Mann-Whitney U test, P<0.001). The results from the receiver operating characteristic analysis showed that the threshold ADC value was 1.84 10(-3) mm(2)/sec with 92.3% sensitivity and 100% specificity for identifying the @entity5 tissues. A significant linear regression correlation was identified between the ADC value of the entire area of the treated mass and the extent of @entity5 @entity39 (r=0.58; P<0.001). In conclusion, DWI can be used to assess @entity157 viability following TACE.
